Petros Pharmaceuticals Inc (NASDAQ:PTPI) — Market Cap & Net Worth
Market Cap & Net Worth: Petros Pharmaceuticals Inc (PTPI)
Petros Pharmaceuticals Inc (NASDAQ:PTPI) has a market capitalization of $101.47K ($101.47K) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31288 globally and #6204 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Petros Pharmaceuticals Inc's stock price $0.05 by its total outstanding shares 2140760 (2.14 Million). Review Petros Pharmaceuticals Inc debt and liabilities to assess the company's total debt and financial obligations.
Petros Pharmaceuticals Inc Market Cap History: 2020 to 2025
Petros Pharmaceuticals Inc's market capitalization history from 2020 to 2025. Data shows change from $94.19 Million to $101.47K (-77.83% CAGR).
Index Memberships
Petros Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #926 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2913 of 3165 |
Weight: Petros Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Petros Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Petros Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.16x
Petros Pharmaceuticals Inc's market cap is 0.16 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $94.19 Million | $9.56 Million | -$20.59 Million | 9.85x | N/A |
| 2021 | $71.29 Million | $7.81 Million | -$9.36 Million | 9.13x | N/A |
| 2022 | $4.99 Million | $5.99 Million | -$27.04 Million | 0.83x | N/A |
| 2023 | $3.02 Million | $5.82 Million | -$8.16 Million | 0.52x | N/A |
| 2024 | $843.25K | $5.11 Million | -$14.32 Million | 0.16x | N/A |
Competitor Companies of PTPI by Market Capitalization
Companies near Petros Pharmaceuticals Inc in the global market cap rankings as of June 18, 2026.
Key companies related to Petros Pharmaceuticals Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #560 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #631 globally with a market cap of $43.86 Billion USD ( CN¥299.75 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #634 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #560 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.27 |
| #631 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $43.86 Billion | CN¥46.99 |
| #634 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
Petros Pharmaceuticals Inc Historical Marketcap From 2020 to 2025
Between 2020 and today, Petros Pharmaceuticals Inc's market cap moved from $94.19 Million to $ 101.47K, with a yearly change of -77.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $101.47K | -87.97% |
| 2024 | $843.25K | -72.06% |
| 2023 | $3.02 Million | -39.48% |
| 2022 | $4.99 Million | -93.00% |
| 2021 | $71.29 Million | -24.32% |
| 2020 | $94.19 Million | -- |
End of Day Market Cap According to Different Sources
On May 21st, 2026 the market cap of Petros Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $101.47K USD |
| MoneyControl | $101.47K USD |
| MarketWatch | $101.47K USD |
| marketcap.company | $101.47K USD |
| Reuters | $101.47K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Petros Pharmaceuticals Inc
Petros Pharmaceuticals, Inc., a healthcare technology company, focuses on developing and licensing proprietary SaaS platform and Software as a medical device web application designed to assist pharmaceutical companies. The company is based in New York, New York.